Anemia

If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Peginesatide Requirements Do Not Differ By Race

Jody A. Charnow May 13, 2012

NATIONAL HARBOR, Md.—Black hemodialysis (HD) patients with anemia require relatively more epoetin than their non-black counterparts to achieve similar hemoglobin (Hb) levels, but blacks and non-blacks required similar peginesatide doses, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Rapid Anemia Management May Reduce Hospital Readmission Rates

Jody A. Charnow May 12, 2012

NATIONAL HARBOR, Md.—Rapid anemia management (RAM) for patients with end-stage renal disease within seven days of hospital discharge decreases their rate of readmission, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Complete Anemia Correction Better for Renal Transplant Patients

John Schieszer April 23, 2012

Completely correcting anemia in kidney transplant recipients may preserve kidney function better than partially correcting anemia.

With ESAs, Let Your Patient Be Your Guide: An Interview with Alan S. Kliger, MD

Delicia Honen Yard April 11, 2012

When using erythropoiesis-stimulating agents (ESAs) to correct anemia in patients with chronic kidney disease, focus less on hitting a given hemoglobin target and more on improving patient-perceived quality of life in such areas as fatigue, weakness, and shortness of breath, advises Alan S. Kliger, MD, Chief Medical Officer and Chief Quality Officer for the Saint Raphael Healthcare System in New Haven, Conn.

FDA Clears Once-Monthly Drug for Anemia in Dialysis Patients

Jody A. Charnow March 27, 2012

The FDA has approved peginesatide (Omontys) for the treatment of anemia in adult dialysis patients.

Correcting Anemia Reduces Odds of Renal Transplant Failure

December 29, 2011

Complete correction of anemia (hemoglobin, 13 g/dL or higher) in kidney transplant recipients slows progression to chronic allograft nephropathy, a study found.

FDA Committee Favors Peginesatide

Stephan Cho December 15, 2011

The FDA's Oncologic Drugs Advisory Committee, in a 15 to 1 vote, has agreed that peginesatide demonstrates a favorable benefit/risk profile for use in treatment of dialysis patients with anemia resulting from chronic kidney disease (CKD).

Novel Therapy for CKD Anemia Advances

Stephan Cho November 16, 2011

PHILADELPHIA—A novel treatment for chronic kidney disease (CKD) patients with anemia is showing positive results following a Phase 1/2 clinical trial, according to findings reported at Kidney Week 2011.

IV Iron Drug Shows Advantages in Head-to-Head Trial

Jody A. Charnow November 12, 2011

PHILADELPHIA—Ferumoxytol has an efficacy comparable to iron sucrose in treating iron deficiency anemia in patients with chronic kidney disease (CKD), but is associated with lower adverse event (AE) rates, according to the findings a head-to-head comparison of the two formulations presented at Kidney Week 2011.

Once-Monthly ESA Maintains Stable Hemoglobin Levels

Jody A. Charnow November 12, 2011

PHILADELPHIA—Once-monthly peginesatide, an investigational peptide-based erythropoiesis stimulating agent (ESA), is similar to epoetin administrated one to three times weekly in maintaining mean hemoglobin levels in the 10-12 g/dL range in hemodialysis patients with anemia, according to study findings presented at Kidney Week 2011.

EPO Use Declining After Bundling Introduced

Jody A. Charnow November 12, 2011

PHILADELPHIA—Epoetin alfa (EPO) use has decreased and intravenous (IV) iron use has increased significantly in private dialysis units since the introduction of the Medicare bundling rule for end-stage renal disease services, data presented at Kidney Week 2011 suggest.

IV Iron Use for Anemia Rising, ESA Use Falling

Jody A. Charnow November 11, 2011

PHILADELPHIA—The use of intravenous (IV) iron for managing anemia in hemodialysis (HD) patients has increased steadily from 2002 to 2008, even after declines in the use of erythropoiesis stimulating agents (ESAs), as reported from data presented at Kidney Week 2011.

HD-Related Damage Not a Factor in CKD-Related Anemia

Jody A. Charnow November 11, 2011

PHILADELPHIA—Mechanical damage to red blood cells (RBC) from hemodialysis (HD) does not contribute to anemia in HD patients, according to study findings presented at Kidney Week 2011.

Response to ESAs Predicts ESRD Risk

Jody A. Charnow November 11, 2011

PHILADELPHIA—Patients with chronic kidney disease (CKD) who have a low response to erythropoiesis-stimulating agents (ESAs) are at increased risk of progressing to end-stage renal disease (ESRD), investigators reported at Kidney Week 2011.

ESA Resistance Increases Death Risk More in HD than PD Patients

Jody A. Charnow November 10, 2011

PHILADELPHIA—Most patients on peritoneal dialysis (PD) receive substantially lower doses of erythropoiesis stimulating agents (ESAs) for the same achieved hemoglobin levels compared with patients on hemodialysis (HD), investigators reported at Kidney Week 2011.

BP Rises with ESAs Not Relate to Vasoconstriction

Jody A. Charnow November 10, 2011

PHILADELPHIA—New study findings may narrow down the possible causes of increased blood pressure (BP) result from the use of erythropoiesis stimulating agents (ESAs) to correct renal anemia, according to a report presented at Kidney Week 2011.

Diabetes Boosts CKD Patients' Comorbidities

Jody A. Charnow November 10, 2011

PHILADELPHIA—Patients with chronic kidney disease (CKD) who also have diabetes have significantly higher rates of anemia, cardiovascular disease, and other comorbidities compared with nondiabetic CKD patients, study findings presented at Kidney Week 2011 show.

Poor Response to ESAs Increases Death Risk in Hemodialysis Patients

Jody A. Charnow September 07, 2011

Mortality in hemodialysis (HD) patients can be influenced by their responsiveness to erythropoiesis-stimulating agents (ESAs), according to Japanese researchers.

FDA Agrees to Review NDA for Peginesatide

Jody A. Charnow July 27, 2011

The FDA has agreed to review a New Drug Application (NDA) for peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult dialysis patients, according to a joint announcement by the two companies colloraborating on the development of the drug.

FDA Recommend More Conservative Dosing of ESAs

Delicia Honen Yard July 13, 2011

The FDA is calling for more conservative dosing of erythropoiesis-stimulating agents (ESAs) when used to treat anemia in CKD patients due to the increased risks of cardiovascular events such as stroke, thrombosis, and death.

Our exclusive coverage of Kidney Week 2011 in Philadelphia includes interviews, videos and noteworthy clinical reports.

Sections: Anemia | Transplantation
Secondary Hyperparathyroidism | General News
More: Videos

Latest CME Article

Renal & Urology News includes a CME article in every print issue, which will also be available online.

View the latest installment:

Managing Bone Disease in  Kidney Transplant Recipients

Renal Nutrition Update

High Protein Intake May Elevate Levels of Advanced Glycation End Products

Advanced glycation end products (AGEs) are byproducts of non-enzymatic chemical reactions between sugars and amino acids, lipids, or DNA. A wide range of molecules fall into this category.

Your Practice

The move from ICD-9-CM to ICD-10 is enough to strike fear into the hearts of physicians and staff alike. Making the leap from 14,000 codes to almost 69,000, topped with the huge cost to make that change, is understandably daunting.

Read more on
Coping with ICD-10

Have any practice management topics that you'd like us to cover?
Let us know.

Expert Q&A

Optimal Sequencing of the New Prostate Cancer Drugs: An Interview with E. David Crawford, MD

Several new drugs have become available for treating advanced prostate cancer in the past year and a half. Dr. Crawford talks to Renal & Urology News about the possible ways in which these drugs might be used.